Stable Metal–Organic Frameworks with Group 4 Metals: Current Status and Trends | ACS Central Science
![Frontiers | The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition Frontiers | The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition](https://www.frontiersin.org/files/Articles/610903/fcell-08-610903-HTML/image_m/fcell-08-610903-g001.jpg)
Frontiers | The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition
![Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges? - European Urology Oncology Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges? - European Urology Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c2134682-eb64-43a4-aafc-269e7c08849c/gr1_lrg.jpg)
Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges? - European Urology Oncology
![Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After ... Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After ...](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/po/2022/po.2022.6/po.21.00446/20220812/images/keyimage.jpg)
Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After ...
![Molecules | Free Full-Text | Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs | HTML Molecules | Free Full-Text | Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs | HTML](https://www.mdpi.com/molecules/molecules-27-03678/article_deploy/html/images/molecules-27-03678-g001.png)
Molecules | Free Full-Text | Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs | HTML
![New developments in the biology of fibroblast growth factors - Ornitz - 2022 - WIREs Mechanisms of Disease - Wiley Online Library New developments in the biology of fibroblast growth factors - Ornitz - 2022 - WIREs Mechanisms of Disease - Wiley Online Library](https://wires.onlinelibrary.wiley.com/cms/asset/616ca467-bd3d-4bf6-b4dc-8164166384fe/wsbm1549-toc-0001-m.jpg)
New developments in the biology of fibroblast growth factors - Ornitz - 2022 - WIREs Mechanisms of Disease - Wiley Online Library
ESPNcricinfo - Four overs 24 runs Two wickets 11 dots Just Jasprit Bumrah things 🔥 #IPL2021 ⏩ es.pn/IPL2021-M42 | Facebook
![Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing | British Journal of Cancer Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-022-01908-1/MediaObjects/41416_2022_1908_Fig1_HTML.png)
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing | British Journal of Cancer
Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials U
![First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis - European Journal of Cancer First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a82aa05d-9fcc-4653-a215-ee5bf567ea54/gr1a_lrg.jpg)
First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis - European Journal of Cancer
Efficient and Selective Uptake of TcO4– by a Cationic Metal–Organic Framework Material with Open Ag+ Sites | Environmental Science & Technology
![Cancers | Free Full-Text | Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation Cancers | Free Full-Text | Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation](https://www.mdpi.com/cancers/cancers-14-02594/article_deploy/html/images/cancers-14-02594-g001.png)
Cancers | Free Full-Text | Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor | Journal of Medicinal Chemistry
![IJMS | Free Full-Text | Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer | HTML IJMS | Free Full-Text | Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer | HTML](https://www.mdpi.com/ijms/ijms-23-08878/article_deploy/html/images/ijms-23-08878-g001.png)
IJMS | Free Full-Text | Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer | HTML
![Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis - European Journal of Cancer Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/6fa01285-0d7b-40e9-a367-e34959259d2b/gr1_lrg.jpg)